ACADIA Pharmaceuticals, Inc. (ACAD)
27.83
+0.09
(+0.32%)
USD |
NASDAQ |
Sep 11, 16:00
27.84
0.00 (0.00%)
After-Hours: 20:00
ACADIA Pharmaceuticals Enterprise Value : 3.908B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 3.908B |
| September 10, 2026 | 3.892B |
| September 09, 2026 | 3.882B |
| September 08, 2026 | 3.865B |
| September 04, 2026 | 3.941B |
| September 03, 2026 | 3.913B |
| September 02, 2026 | 4.097B |
| September 01, 2026 | 4.090B |
| August 31, 2026 | 4.094B |
| August 28, 2026 | 4.128B |
| August 27, 2026 | 4.235B |
| August 26, 2026 | 4.209B |
| August 25, 2026 | 4.379B |
| August 24, 2026 | 4.221B |
| August 21, 2026 | 4.195B |
| August 20, 2026 | 4.116B |
| August 19, 2026 | 4.317B |
| August 18, 2026 | 4.312B |
| August 17, 2026 | 4.111B |
| August 14, 2026 | 3.978B |
| August 13, 2026 | 4.002B |
| August 12, 2026 | 4.187B |
| August 11, 2026 | 4.180B |
| August 10, 2026 | 4.176B |
| August 07, 2026 | 4.145B |
| Date | Value |
|---|---|
| August 06, 2026 | 4.015B |
| August 05, 2026 | 4.075B |
| August 04, 2026 | 3.791B |
| August 03, 2026 | 3.526B |
| July 31, 2026 | 3.570B |
| July 30, 2026 | 3.687B |
| July 29, 2026 | 3.651B |
| July 28, 2026 | 3.595B |
| July 27, 2026 | 3.488B |
| July 24, 2026 | 3.393B |
| July 23, 2026 | 3.391B |
| July 22, 2026 | 3.414B |
| July 21, 2026 | 3.495B |
| July 20, 2026 | 3.436B |
| July 17, 2026 | 3.524B |
| July 16, 2026 | 3.529B |
| July 15, 2026 | 3.579B |
| July 14, 2026 | 3.505B |
| July 13, 2026 | 3.507B |
| July 10, 2026 | 3.631B |
| July 09, 2026 | 3.663B |
| July 08, 2026 | 3.593B |
| July 07, 2026 | 3.627B |
| July 06, 2026 | 3.553B |
| July 02, 2026 | 3.588B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 19.92B |
| Agios Pharmaceuticals, Inc. | 1.416B |
| Biogen, Inc. | 39.14B |
| Insmed, Inc. | 27.83B |
| Arcutis Biotherapeutics, Inc. | 2.875B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.50M |
| Revenue (Quarterly) | 307.96M |
| Total Expenses (Quarterly) | 276.46M |
| EPS Diluted (Quarterly) | 0.1822 |
| Gross Profit Margin (Quarterly) | 90.81% |
| Profit Margin (Quarterly) | 10.23% |
| Earnings Yield | 7.98% |
| Operating Earnings Yield | 1.81% |
| Normalized Earnings Yield | 7.978 |